VIRMA and neoplasm: In our study, we first analyzed the expression level of reported 17 (METTL3, METTL14, WTAP, RBM15, RBM15B, VIRMA, ZC3H13, HNRNPA2B1, HNRNPC, YTHDF1, YTHDF2, YTHDC1, YTHDC2, IGF2BP1, IGF2BP3, FTO, and ALKBH5) m6A-related regulators across 33 cancer types and analyzed the differential expression, tumor microenvironment, immune subtype, and drug sensitivity of m6A-related regulators of 33 cancer types.